A specific cell signaling protein may be used to enhance the sensitivity of medulloblastoma tumors to immunotherapy, potentially improving quality of life for patients with the malignant pediatric brain cancer.
Northwestern Medicine investigators have discovered that the growth of cancerous tumors requires the activation of a specific biochemical process within the mitochondria of tumor cells, showing potential as a new target for cancer therapy.
An emerging cancer treatment also helps prevent cells from turning into viral factories by interfering with HIV infection processes inside the cell, according to a recent study.
A new immunotherapy developed by investigators at Northwestern University dramatically extends the survival time of mice with triple negative breast cancer, one of the most aggressive and difficult-to-treat forms of breast cancer.
Cancer patients with other comorbidities have a higher risk of dying from complications due to COVID-19, and should discuss the risks and benefits of continuing cancer treatment with their physician, according to a recent study.
A novel drug called enzalutamide may extend overall survival for men with nonmetastatic, castration-resistant prostate cancer, according to findings from clinical trial published in The New England Journal of Medicine.
A novel compound using diphtheria toxin to attack a signaling pathway implicated in as many as 50 percent of cancers slowed tumor growth, according to a recent study.
A protein called mDia2 is vital for proper bone marrow transplantation, according to a new study.
Machine-learning technology could help pathologists more accurately assess how a patient’s immune system is responding to breast cancer, according to a recent series of reports authored in part by Feinberg faculty.
A genetic screen has revealed previously unknown regulators of Foxp3, a transcription factor that, when deactivated, may improve patient response to aggressive cancers.